Antimicrobial resistance in Staphylococcus aureus

Microbes and Infection

Volumn 1, Issue 10, 1999, Pages 795-805

  Smith, Theresa L ^a   Jarvis, William R ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Antimicrobials; Resistance; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; FUSIDIC ACID; GLYCOPEPTIDE; IMIPENEM; LINCOSAMIDE; MACROLIDE; METICILLIN; NOVOBIOCIN; NUCLEIC ACID SYNTHESIS INHIBITOR; PENICILLIN G; PROTEIN SYNTHESIS INHIBITOR; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; STREPTOGRAMIN; SULFAMETHOXAZOLE; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL MUTATION; BACTERIUM CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; HOSPITAL INFECTION; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 0032706979     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80082-3     Document Type: Review

References (101)

1. Massova I., Mobashery S., Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases, Antimicrob. Agents Chemother. 42 (1998) 1-17.
2. Al-Masaudi S.B., Day M.J., Russell A.D., Antimicrobial resistance and gene transfer in Staphylococcus aureus, J. App. Bacteriol. 70 (1991) 279-290.
3. Hickey S.M., Nelson J.D., Mechanisms of antibacterial resistance, Ad. Pediatr. 44 (1997) 1-41.
4. Ogston A., Micrococcus poisoning, J. Anal. Physiol. 17 (1883)24-58.
5. Archer G.L., Staphylocoaus aureus: a well-armed pathogen, Clin. Infect. Dis. 26(1998)1179-1181.
6. Gorbach S.L., Antimicrobial resistance in the!990s, Infect. Dis. Clin. Prac. 5 (1996) S32-S36.
7. Emori T.G., Gaynes R.P., An overview of nosocomial infections including the role of the microbiology laboratory, Clin. Micro. Rev. 6 (1993) 428-442.
8. Banerjee S.N., Emori T.G., Culver D.H., Gaynes R.P., Jarvis W.R., Horan T., Edwards J.R., Henderson T., Martone W.J., the National Nosocomial Infections Surveillance System., Secular trends in nosocomial primary bloodstream infections in the United States 1980-1989, Amer. J. Med. 91 (1991) 86S-89S.
9. Skinner D., Keefer C.S., Significance of bacteremia caused by Staphylococcus aureus, Arch. Intern. Med. 68 (1941) 851-875.
10. Handwerger S., Tomasz A., Antibiotic tolerance among clinical isolates of bacteria, Rev. Infect. Dis. 7 (1985) 368-386.
11. Chain E., Florey H.W., Gardner A.D., Heatley N.G., Jennings M.A., Orr-Ewing J., Sanders A.G., Penicillin as a chemotherapeutic agent, Lancet 2 (1940) 226-228.
12. Abraham E.P., Chain E., An enzyme from bacteria able to destroy penicillin, Nature 146 (1940) 837-837.
13. Harper G.J., Inhibition of penicillin in routine culture media, Lancet 2 (1943) 569-571.
14. Kirby W.M.M., Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci, Science 99(1944)452-453.
15. Rammelkamp C.H., Maxon T., Resistance of Staphylococcus aureus to the action of penicillin, Proc. Soc. Exp. Biol. Med. 51 (1942)386-389.
16. Medeiros A.A., Evolution and dissemination of B-lactamases accelerated by generations of b-lactam antibiotics, Clin. Infect. Dis. 24 (1997) S19-S45.
17. Hackbarth C.J., Kocagoz T., Kocagoz S., Chambers H.F., Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance, Antimicrob. Agents Chemother. 39 (1995) 103-106.
18. Livermore D.M., B-lactamases in laboratory and clinical resistance, Clin. Micro. Rev. 8 (1995) 557-584.
19. Brumfitt W., Hamilton-Miller J., Methicillin-resistant Staphylococcus aureus, N. Engl. J. Med. 320 (1989) 1188-1196.
20. Jevons M.P., Coe A.W., Parker M.T., Methicillin resistance in staphylococci, Lancet 1 (1963) 904-907.
21. Ayliffe G.A.J., The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus, Clin. Infect. Dis. 24(1997)874-579.
22. Panlilio A.L., Culver D.H., Gaynes R.P., Banerjee S.N., Henderson T.S., Toison J.S., Martone W.J., The National Nosocomial Infections Surveillance System, Methicillin-resistant Staphylococcus aureus in US hospitals 1975-1991, Infect. Contrl. Hosp. Epidemiol. 13 (1992) 582-586.
23. Haley R.W., Hightower A.W., Khabbaz R.F., Thornsberry C., Martone W.J., Alien J.R., Hughes J.M., The emergence of methicillin-resistant Staphylococcus aureus infections in United States hospitals, Ann. Intern. Med. 97 (1982) 297-308.
24. Boyce J.M., Landry M., Deetz T.R., Dupont H.L., Epidemiologie studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections, Infect. Contrl. 2 (1981) 110-116.
25. Chambers H.F., Sachdeva M., Binding of B-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus, J. Infect. Dis. 161 (1990) 1170-1176.
26. Wu S., Piscitelli C., DeLencastre H., Tomasz A., Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri, Microbial. Drug. Res. 2 (1996) 435-441.
27. Henze U.U., Berger-BŠchi B., Staphylococcus aureus, penicillin-binding protein 4 and intrinsic B-lactam resistance, Antimicrob. Agents Chemother. 39 (1995) 2415-2422.
28. Wilhelm M.P., Vancomycin, Mayo. Clin. Proc. 66 (1991) 1165-1170.
29. Levine J.F., Vancomycin: a review, Med. Clin. N. Amer. 71 (1987) 1135-1145.
30. Geraci J.E., Heilman F.R., Nichols D.R., Weilman W.E., Ross G.T., Some laboratory and clinical experiences with a new antibiotic, Proc. Staff. Meetings, of. Mayo. Clinic. 31 (1956) 564-582.
31. Edmond M.B., Wenzel R.P., Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control, Ann. Intern. Med. 124 (1996) 329-334.
32. Cherubin C.E., Corrado M.L., SierraM.F., Gombert M.E., Shulman M., Susceptibility of Gram-positive cocci to various antibiotics including cefotaxime moxalactam and N-formimidoyl thienamycin, Antimicrob. Agents Chemother. 20 (1981) 553-555.
33. Tuazon C.U., Miller H., Clinical and microbiologie aspects of serious infections caused by Staphylococcus epidermidis, Scand. J. Infect. Dis. 15 (1983) 347-360.
34. Sanyal D., Johnson A.P., George R.C., Cookson B.D., Williams A.J., Peritonitis due to vancomycin-resistant Staphylococcus epidermidis, Lancet 54 (1991) 337.
35. Morris JrJ.G., Shay D.K., Hebden J.N., McCarterJr R.J., Perdue B.E., Jarvis W.R., Johnson J.A., Dowling T.C., Polish L.B., Schwalbe R.S., Enterococci resistant to multiple antimicrobial agents including vancomycin: establishment of endemicity in a university medical center, Ann. Intern. Med. 123 (1995) 250-259.
36. Noble W.C., Virani Z., Cree R.G., Co-transfer of vancomycin and other resistance genes from Enterococcus. faecalis NCTC 12201 to Staphylococcus aureus, FEMS Microbiol. Lett. 93 (1992) 196-198.
37. Schwalbe R.S., Stapleton J.T., Gilligan P.H., Emergence of vancomycin resistance in coagulase-negative staphylococci, N. Engl. J. Med. 316 (1987) 927-931.
38. Aubert G., Passot S., Lucht F, Dorche G., Selection of vancomycin- and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of Staphylococcus epidermidis infection, J. Antimicrob. Chemother. 25 (1990)491-493.
39. Veach L.A., Pfaller M.A., Barrett M., Koontz F.F., Wenzel R.P., Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection, J. Clin. Microbiol. 28 (1990) 2064-2068.
40. Sanyal D., Williams A.J.Johnson A.P., George R.C., The emergence of vancomycin resistance in renal dialysis, J. Hosp. Infect. 24 (1993) 167-173.
41. Garrett D.O., Jochimsen E., Murfitt K., Hill B.C., McAllister S., Nelson P., Spera R., Sail R., Tenover P.C., Jarvis W.R., The impending apocalypse: the emergence of vancomycin resistance in Staphylococcus spp., Infect. Contrl. Hosp. Epidemiol. 18 Abstract. (1997)
42. Schwalbe R.S., Ritz W.J., Verma P.R., Gilligan P.H., Barranco E.A., Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus, J. Infect. Dis. 161 (1990)45-51.
43. Herwaldt L., Boyken L., Pfaller M.A., In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis, Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 1007-1012.
44. Watanakunakorn C, In vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin, J. Antimicrob. Chemother. 22 (1988) 321-324.
45. Daum R.S., Gupta S., Sabbagh R., Milewski W.M., Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility, J. Infect. Dis. 166 (1992) 1066-1072.
46. Biavasco F., Giovanetti E., Montanari M., Lupidi R., Varaldo P., Development of in vitro resistance toglycopeptide antibiotics: assessment in staphylococci of different species, J. Antimicrob. Chemother. 27 (1991) 71-79.
47. Sieradzki K., Tomasz A., A highly vancomycin-resistant laboratory mutant of Staphylcoccusaureus, FEMS Microbiol. Lett. 142 (1996) 161-166.
48. Goldstein F.W., Coutrot A., Sieffer A., Acar J.F., Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci, Antimicrob. Agents Chemother. 34 (1990) 899-900.
49. Krcmery Jr V., Trupl J., Drgona L., Lacka J., Kukuckova E., Oravcova E., Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer neutropenia and previous treatment with vancomycin, Eur. J. Clin. Microbiol. Infect. Dis. 15 (1996)259-261.
50. Shlaes D.M., Shlaes D.H., Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin, Clin. Infect. Dis. 20(1995) 1071-1072.
51. Sieradzki K., Villari P., Tomasz A., Low-level teicoplanin resistance and heteroresistance to vancomycin, Ann. Intern. Med. 128 (1998) 245-245.
52. Sanyal D., Greenwood D., An electronmicroscope study of glycopeptide antibiotic-resistant strains of Staphylococcus epidemidis, J. Med. Microbiol. 39 (1993) 204-210.
53. Billot-Klein D., Gutmann L., Bryant D., Bell D., Van-Heijenoort J., Grewal J., Shlaes D.M., Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics, J. Bacteriol. 178 (1996)4696-4703.
54. Sieradzki K., Tomasz A., Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus, J. Bacteriol. 179 (1997)2557-2566.
55. Tenover F.C., Lancaster M.V., Hill B.C., Steward C.D., Stocker S.A., Hancock G.A., O'Hara CM., Clark N.C., Hiramatsu K., Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides, J. Clin. Microbiol. 36 (1998) 1020-1027.
56. Centers for Disease Control and Prevention, Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan996, Morb. Mortal. Weekly Report 46 (1997), 624-626.
57. Hiramatsu K., Hahaki H., Ino T., Yabuta K., Oguri T., Tenover F.C., Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J. Antimicrob. Chemother. 40 (1997) 135-146.
58. Centers for Disease Control and Prevention, Staphylococcus aureus, with reduced susceptibility to vancomycin - United States 1997, Morb. Mortal. Weekly Report 46 (1997)765-766.
59. Centers for Disease Control and Prevention, Update: Staphylococcus aureus, with reduced susceptibility to vancomycin-United Statesl997, Morb. Mortal. Weekly Report 46 (1997) 813-815.
60. Sieradzki K., Roberts R.B., Serur D., Hargrave J., Tomasz A., Recurrent peritonitis in a patient on dialysis and prophylactic vancomycin, Lancet 351 (1998) 880-881.
61. Ploy M.C., Grélaud C, Martin C, deLumley L., Denis F., First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital, Lancet 351 (1998) 1212-1212.
62. Howe R.A., Bowker K.E., Walsh T.R., Feest T.G., Macgowan A.P., Vancomycin-resistant Staphylococcus aureus, Lancet 351 (1998) 602-602.
63. Centers for Disease Control and Prevention, Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin, Morb. Mortal. Weekly Report 46 (1997) 626-628-635.
64. Hiramatsu K., Aritaka N., Hanaki H., Kawasaki S., Hosoda Y., Hori S., Fukuchi Y, Kobayashi I., Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, Lancet 350 (1997) 1670-1673.
65. Kréméryjr V., Hanzen J., Ciznar P., Brezaniova T., Vancomycin-resistant Staphylococcus aureus in an immunocompromised child with Job's syndrome, Antibiot. Chemother. (1997) 1-6.
66. Shanson D.C., Antibiotic-resistant Staphylococcus aureus, J. Hosp. Infect. 2(1981)11-36.
67. Toma E., Barriault D., Antimicrobial activity of fusidic acid and disk diffusion susceptibility testing criteria for gram-positive cocci, J. Clin. Microbiol. 33 (1995) 1712-1715.
68. Weisblum B., Erythromycin resistance by ribosome modificaton, Antimicrob. Agents Chemother. 39 (1995) 577-585.
69. Chabbert Y.A., Courvalin P., Synergie des composants des antibiotiques du groupe de la streptogramine, Pathologie Biologie 19 (1971) 613-619.
70. Contreras A., Vazquez D., Synergistic interaction of the streptogramins with the ribosome, Eur. J, Biochem. 74 (1977)549-551.
71. Low D.E., Nadler H.L., A review of in vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus, J. Antimicrob. Chemother. 39 (1997) 53-58.
72. Bertino J.S., Jr Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus, Amer. J. Health-System. Pharm. 54 (1997) 2185-2191.
73. Kluytmans J.A.J.W., Manders M.J., VanBommel E., Verbrugh H., Elimination of nasal carriage of Staphylococcus aureus, in hemodialysis patients, Infect. Contrl. Hosp. Epidemiol. 17 (1996) 793-797.
74. Janssen D.A., Zarins L.T., Schaberg D.R., Bradley S.E, Terpenning M.S., Kauffman C.A., Detection and characterization of mupirocin resistance in Staphylococcus aureus, Antimicrob. Agents Chemother. 37 (1993) 2003-2006.
75. Gilbart J., Perry C.R., Slocombe B., High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleycyl-tRNA sythetases, Antimicrob. Agents Chemother. 37 (1993) 32-38.
76. Neu H.C., The crisis in antibiotic resistance, Science 257 (1992) 1064-1072.
77. dos Santos K.R.N., deSouza Fonseca L., GontijoFilho P.P., Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals, Infect. Contrl. Hosp. Epidemiol. 17(1996)813-816.
78. Ng E.Y., Trucksis M., Hooper D.C., Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoesomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus, Antimicrob. Agents Chemother. 40 (1996) 1881-1888.
79. Schmitz F.J.Jones M.E., Hofmann B., Hansen B., Scheuring S., Luckefahr M., Fluit A., Verhoef J., Hadding U., Heinz H.P., Kohrer K., Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus, and effects of mutations on ciprofloxacin MIC, Antimicrob. Agents Chemother. 42 (1998) 1249-1252.
80. Kaatz G.S., Seo S.M., Ruble CA., Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus, Antimicrob. Agents Chemother. 37 (1993) 1086-1094.
81. Acar J.F., Goldstein F.W., Trends in bacterial resistance to fluoroquinolones, Clin. Infect. Dis. 24 (1997) S67-S73.
82. Blumberg H.M., Rimland D., Carroll D.J., Terry P., Wachsmith I.K., Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus, J. Infect. Dis. 163 (1991) 1279-1285.
83. Coronado V.G., Edwards J.R., Culver D.H., Gaynes R.P., the National Nosocomial Infections Surveillance System, Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States, Infect. Contrl. Hosp. Epidemiol. 16 (1995) 71-75.
84. Jones R.N., Relier L.B., Rosati L.A., Erwin M.E., Sanchez M.L., The Ofloxacin Surveillance Group, Ofloxacin a new broad-spectrum fluoroquinolone, Diag. Microbiol. Infect. Dis. 15(1992)425-434.
85. Eliopoulos G.M., In vitro activity of fluoroquinolones against gram-positive bacteria, Drugs 49 (1995) 48-57.
86. Stieger M., Angehrn P., Wohlgensinger B., Gmunder H., GyrB mutations in Staphylococcus aureus, strains resistant to cyclothialidine coumermycin and novobiocin, Antimicrob. Agents Chemother. 40 (1996) 1060-1062.
87. Jones R.N., Should novobiocin be clinically re-evaluated? Diag. Microbiol. Infect. Dis. 12 (1989) 363-365.
88. Huovinen P., Sundstrom L., Swedberg G., Skšld O., Trimethoprim and sulfonamide resistance, Antimicrob. Agents Chemother. 39 (1995) 279-290.
89. Spratt B.G., Resistance to antibiotics mediated by target alterations, Science 264 (1994) 388-393.
90. Then R.L., Riggenbach H., Dihydrofolate reductases in some folate-requiring bacteria with low trimethoprim susceptibility, Antimicrob. Agents Chemother. 14 (1978) 112-117.
91. Rouch D.A., Messerotti L.J., Loo L.S., Jackson C.A., Skurray R.A., Trimethoprim resistance transposon Tn4004 from Staphylococcus aureus encodes genes for a dihydrofolate reductase and thymidylate syhthetase flanked by three copies of IS257, Mol. Microbiol. 3 (1989) 161-175.
92. Then R.L., Kohl I., Burdeska A., Frequency and transferability of trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, J. Chemother. 4 (1992) 67-71.
93. Torralba M.D., Frey S.E., Lagging L.M., Treatment of methicillin-resistant Staphylococcus aureus infection with quinupristin/dalfopristin, Clin. Infect. Dis. 21 (1995) 460-461.
94. Watanakunakorn C, Axelson C., Bota B., StahlCharlotte J., Mupirocin ointment with and without chlorhexidine baths in the eradication Staphylococcus aureus nasal carriage in nursing home residents, Am. J. Infect. Contrl. 23 (1995) 306-309.
95. Thornsberry C., The development of antimicrobial resistance in staphylococci, J, Antimicrob. Chemother. 21 (1988)9-16.
96. Sheagren J.N., Staphylococcus aureus the persistent pathogen (second of two parts), N. Engl. J. Med. 310 (1984) 1437-144.
97. MarkowitzN., SaravolatzL., PohlodD., Salo S., QuinnE., Somerville M., delBusto R., Cardenas J., Rathod M., Fisher E., Comparative efficacy and toxicity of trimethoprim-sulfamethoxazole (TS) versus vancomycin (V) in the therapy of serious S. aureus (SA) infections, 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV, October, 1983, pp. 23-26.
98. Prieto J., Aguilar L., Giménez M.J., Toro D., Gmez-Lus M.L., Dal R.R., Balcabao I.P., In vitro activities of coamoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin, Antimicrob. Agents Chemother. 42 (1998) 1574-1577.
99. Mulazimoglu L., Drenning S.D., Yu V.L., In vitro activities of two novel oxazolidinones (U100592 and U100766) a new fluoroguinolone (trovofloxacin) and dalfopristinquinupristin against Staphylococcus aureus, and Staphylococcus epidermidis, Antimicrob. Agents Chemother. 40 (1996) 2428-2430.
100. Cormican M.G., Jones R.N., Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci staphylococci and nonpneumococcal streptococci, Drugs 51(1996)6-12.
101. Gaynes R.P., The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals, Infect. Dis. Clin. N. Amer. 11 (1997) 757-765.